Biosimilar Statistical Guidance Will Stress Flexibility, Woodcock Says
Executive Summary
Analytical similarity approaches for biosimilars will not be 'rigid' like small-molecule generic bioequivalence.
You may also be interested in...
FDA Biosimilar Education Campaign Will Need To Be Targeted
Sen. Cassidy does not think additional appropriations are needed for a massive provider and patient education on biosimilars.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
US FDA Hopes Food, Inspection Office Reorg Bolsters Innovative Clinical Trial Adoption
Ensuring inspectors understand the innovative trial designs in use before an inspection will be important to increasing industry confidence in their use, CDER Director Patrizia Cavazzoni said.